Effect of quercetin on doxorubicin cytotoxicity in sensitive and resistant human MCF7 breast cancer cell lines

Almohammad Aljabr,Bayan; Zihlif,Malek; Abu-Dahab,Rana; Zalloum,Hiba

doi:10.3892/br.2024.1745

Effect of quercetin on doxorubicin cytotoxicity in sensitive and resistant human MCF7 breast cancer cell lines

Authors:
- Bayan Almohammad Aljabr
- Malek Zihlif
- Rana Abu-Dahab
- Hiba Zalloum
View Affiliations

Affiliations: Department of Pharmacology, School of Medicine, The University of Jordan, Amman 11942, Jordan, Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, The University of Jordan, Amman 11942, Jordan, Hamdi Mango Research Center for Scientific Research, The University of Jordan, Amman 11942, Jordan
Published online on: February 5, 2024 https://doi.org/10.3892/br.2024.1745
Article Number: 58
Copyright: © Almohammad Aljabr et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemoresistance is the major cause of cancer recurrence, relapse and eventual death. Doxorubicin resistance is one such challenge in breast cancer. The use of quercetin, an antioxidant, in combination with doxorubicin has been investigated for offering protection to normal cells from the toxic side effects of doxorubicin in addition to modulation of its resistance. The present study aimed to investigate the effects of quercetin in prevention of a doxorubicin‑chemoresistant phenotype in both doxorubicin‑sensitive and ‑resistant human MCF‑7 breast cancer cell lines. A doxorubicin‑resistant MCF‑7 cell line was established. The development of resistant cells was closely monitored for changes in morphological features. Sensitivity to doxorubicin and the doxorubicin/quercetin combination was assessed using the tetrazolium assay. To determine the mechanism by which quercetin sensitizes the doxorubicin MCF‑7‑resistant cell line to doxorubicin, gene expression alterations in breast cancer‑related genes were examined using the reverse transcription‑quantitative PCR (RT‑qPCR) array technology. Resistant MCF cells were successfully developed and the inhibitory concentration (IC₅₀) value of doxorubicin increased from 0.133 to 4 µM (wild‑type to resistant). The effects of the quercetin/doxorubicin combination exhibited different effects on wild‑type vs. resistant cells. The IC50 of doxorubicin was reduced in wild cells, whereas resistant cells showed an increase in cell viability at lower concentrations and a potentiation of the effects of doxorubicin only at higher concentrations. Annexin V/propidium iodide staining demonstrated that quercetin drives cells into late apoptosis and necrosis, but in resistant cells, necrosis predominates. RT‑qPCR results revealed that quercetin led to a reversal in doxorubicin effects via up‑ and downregulation of important genes such as SNAI2, PLAU and CSF1 genes. Downregulation of cell migration genes, SNAI2 (‑31.23‑fold) and plasminogen activator, urokinase (PLAU; ‑30.62‑fold), and the apoptotic pathway gene, colony stimulating factor 1 (CSF1; ‑17.25‑fold) were the most important querticin‑associated events. Other gene alterations were also observed involving cell cycle arrest and DNA repair pathways. The results of the present study indicated that quercetin could lead to a reversal of doxorubicin resistance in breast cancer cells via downregulation of the expression of important genes, such as SNAI2, PLAU and CSF1. Such findings may represent a potential strategy for reversing breast cancer cell‑related chemoresistance.

View Figures

View References

1	Gucalp A, Gupta GP, Pilewskie ML, Sutton EJ and Norton L: Advances in managing breast cancer: A clinical update. F1000Prime Rep. 6(66)2014.PubMed/NCBI View Article : Google Scholar
2	Wilson TR, Longley DB and Johnston PG: Chemoresistance in solid tumours. Ann Oncol. 17 (Suppl 10):x315–x324. 2006.PubMed/NCBI View Article : Google Scholar
3	Prihantono and Faruk M: Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it? Ann Med Surg (Lond). 70(102793)2021.PubMed/NCBI View Article : Google Scholar
4	Marquette C and Nabell L: Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol. 13:263–275. 2012.PubMed/NCBI View Article : Google Scholar
5	Wang X, Zhang H and Chen X: Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2:141–160. 2019.PubMed/NCBI View Article : Google Scholar
6	Moulder S: Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond). 6:821–830. 2010.PubMed/NCBI View Article : Google Scholar
7	Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I, Danesi R and Mini E: Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat. 14:280–296. 2011.PubMed/NCBI View Article : Google Scholar
8	Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A and Verrill MW: Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 20:816–827. 2009.PubMed/NCBI View Article : Google Scholar
9	Shi Y, Bieerkehazhi S and Ma H: Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells. Int J Clin Exp Pathol. 11:2347–2355. 2018.PubMed/NCBI
10	Smith L, Watson MB, O'Kane SL, Drew PJ, Lind MJ and Cawkwell L: The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther. 5:2115–2120. 2006.PubMed/NCBI View Article : Google Scholar
11	AbuHammad S and Zihlif M: Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics. 101:213–220. 2013.PubMed/NCBI View Article : Google Scholar
12	Li X, Lu Y, Liang K, Liu B and Fan Z: Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res. 7:R589–R597. 2005.PubMed/NCBI View Article : Google Scholar
13	Lee ER, Kim JY, Kang YJ, Ahn JY, Kim JH, Kim BW, Choi HY, Jeong MY and Cho SG: Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim Biophys Acta. 1763:958–968. 2006.PubMed/NCBI View Article : Google Scholar
14	Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR and Mossman BT: Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer. 9(314)2010.PubMed/NCBI View Article : Google Scholar
15	Shi Y, Moon M, Dawood S, McManus B and Liu PP: Mechanisms and management of doxorubicin cardiotoxicity. Herz. 36:296–305. 2011.PubMed/NCBI View Article : Google Scholar
16	Elmadany N, Khalil E, Vaccari L, Birarda G, Yousef I and Abu-Dahab R: Antiproliferative activity of the combination of doxorubicin/quercetin on MCF7 breast cancer cell line: A combined study using colorimetric assay and synchrotron infrared microspectroscopy. Infrared Phys Technol. 95:141–147. 2018.
17	Yang F, Teves SS, Kemp CJ and Henikoff S: Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta. 1845:84–89. 2014.PubMed/NCBI View Article : Google Scholar
18	Barbeau D, Persoons R, Marques M, Hervé C, Laffitte-Rigaud G and Maitre A: Relevance of urinary 3-hydroxybenzo(a)pyrene and 1-hydroxypyrene to assess exposure to carcinogenic polycyclic aromatic hydrocarbon mixtures in metallurgy workers. Ann Occup Hyg. 58:579–590. 2014.PubMed/NCBI View Article : Google Scholar
19	Huang ZP, Liu XJ, Zou BX, Wang LG and Zhou T: The complete recanalization of PICC-related venous thrombosis in cancer patients: A series of case reports. Exp Ther Med. 6:411–412. 2013.PubMed/NCBI View Article : Google Scholar
20	Hashemzaei M, Delarami Far A, Yari A, Heravi RE, Tabrizian K, Taghdisi SM, Sadegh SE, Tsarouhas K, Kouretas D, Tzanakakis G, et al: Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo. Oncol Rep. 38:819–828. 2017.PubMed/NCBI View Article : Google Scholar
21	Slighoua M, Amrati FE, Chebaibi M, Mahdi I, Al Kamaly O, El Ouahdani K, Drioiche A, Saleh A and Bousta D: Quercetin and ferulic acid elicit estrogenic activities in vivo and in silico. Molecules. 28(5112)2023.PubMed/NCBI View Article : Google Scholar
22	Notas G, Nifli AP, Kampa M, Pelekanou V, Alexaki VI, Theodoropoulos P, Vercauteren J and Castanas E: Quercetin accumulates in nuclear structures and triggers specific gene expression in epithelial cells. J Nutr Biochem. 23:656–666. 2012.PubMed/NCBI View Article : Google Scholar
23	Liu Y, Liu C, Tang C and Yin C: Dual stimulus-responsive chitosan-based nanoparticles co-delivering doxorubicin and quercetin for cancer therapy. Mater Lett. 305(130826)2021.
24	Henidi HA, Al-Abbasi FA, El-Moselhy MA, El-Bassossy HM and Al-Abd AM: Despite blocking doxorubicin-induced vascular damage, quercetin ameliorates its antibreast cancer activity. Oxid Med Cell Longev. 2020(8157640)2020.PubMed/NCBI View Article : Google Scholar
25	Chen JY, Hu RY and Chou HC: Quercetin-induced cardioprotection against doxorubicin cytotoxicity. J Biomed Sci. 20(95)2013.PubMed/NCBI View Article : Google Scholar
26	Li S, Yuan S, Zhao Q, Wang B, Wang X and Li K: Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it. Biomed Pharmacother. 100:441–447. 2018.PubMed/NCBI View Article : Google Scholar
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
28	Li SZ, Li K, Zhang JH and Dong Z: The effect of quercetin on doxorubicin cytotoxicity in human breast cancer cells. Anticancer Agents Med Chem. 13:352–355. 2013.PubMed/NCBI View Article : Google Scholar
29	Wang G, Zhang J, Liu L, Sharma S and Dong Q: Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One. 7(e51764)2012.PubMed/NCBI View Article : Google Scholar
30	Shu Y, Xie B, Liang Z and Chen J: Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met. Oncol Lett. 15:2252–2258. 2018.PubMed/NCBI View Article : Google Scholar
31	Huang CF, Liu SH, Ho TJ, Lee KI, Fang KM, Lo WC, Liu JM, Wu CC and Su CC: Quercetin induces tongue squamous cell carcinoma cell apoptosis via the JNK activation-regulated ERK/GSK-3α/β-mediated mitochondria-dependent apoptotic signaling pathway. Oncol Lett. 23(78)2022.PubMed/NCBI View Article : Google Scholar
32	Schuurhuis GJ, Van Heijningen TH, Cervantes A, Pinedo HM, de Lange JH, Keizer HG, Broxterman HJ, Baak JP and Lankelma J: Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br J Cancer. 68:898–908. 1993.PubMed/NCBI View Article : Google Scholar
33	Wang X, Li Y, Fan GF, Zhang TY, Sun B and Fan PS: Effect of verapamil in the reversal of doxorubicin chemotherapy resistance in advanced gastric cancer. Eur Rev Med Pharmacol Sci. 24:7753–7763. 2020.PubMed/NCBI View Article : Google Scholar
34	Rogan AM, Hamilton TC, Young RC, Klecker RW Jr and Ozols RF: Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science. 224:994–996. 1984.PubMed/NCBI View Article : Google Scholar
35	Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT and Alberts DS: Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res. 48:6365–6370. 1988.PubMed/NCBI
36	AlQudah DA, Zihlif MA and Taha MO: Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors. Eur J Med Chem. 110:204–223. 2016.PubMed/NCBI View Article : Google Scholar
37	Li J, Poi MJ and Tsai MD: Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry. 50:5566–5582. 2011.PubMed/NCBI View Article : Google Scholar
38	Srivastava S, Somasagara RR, Hegde M, Nishana M, Tadi SK, Srivastava M, Choudhary B and Raghavan SC: Quercetin, a natural flavonoid interacts with DNA, arrests cell cycle and causes tumor regression by activating mitochondrial pathway of apoptosis. Sci Rep. 6(24049)2016.PubMed/NCBI View Article : Google Scholar
39	Suh DK, Lee EJ, Kim HC and Kim JH: Induction of G(1)/S phase arrest and apoptosis by quercetin in human osteosarcoma cells. Arch Pharm Res. 33:781–785. 2010.PubMed/NCBI View Article : Google Scholar
40	Choi JA, Kim JY, Lee JY, Kang CM, Kwon HJ, Yoo YD, Kim TW, Lee YS and Lee SJ: Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int J Oncol. 19:837–844. 2001.PubMed/NCBI View Article : Google Scholar
41	Zhang M, Zhang H, Tang F, Wang Y, Mo Z, Lei X and Tang S: Doxorubicin resistance mediated by cytoplasmic macrophage colony-stimulating factor is associated with switch from apoptosis to autophagic cell death in MCF-7 breast cancer cells. Exp Biol Med (Maywood). 241:2086–2093. 2016.PubMed/NCBI View Article : Google Scholar
42	Torgovnick A and Schumacher B: DNA repair mechanisms in cancer development and therapy. Front Genet. 6(157)2015.PubMed/NCBI View Article : Google Scholar
43	Roy R, Chun J and Powell SN: BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer. 12:68–78. 2011.PubMed/NCBI View Article : Google Scholar
44	Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR and Venuta S: BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 88:1285–1291. 2003.PubMed/NCBI View Article : Google Scholar
45	Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH and Harkin DP: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 13:7413–7420. 2007.PubMed/NCBI View Article : Google Scholar
46	Kundur S, Prayag A, Selvakumar P, Nguyen H, McKee L, Cruz C, Srinivasan A, Shoyele S and Lakshmikuttyamma A: Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines. J Cell Physiol. 234:11103–11118. 2019.PubMed/NCBI View Article : Google Scholar
47	Alves CL, Elias D, Lyng MB, Bak M and Ditzel HJ: SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res. 20(60)2018.PubMed/NCBI View Article : Google Scholar
48	Côme C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C and Savagner P: Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res. 12:5395–5402. 2006.PubMed/NCBI View Article : Google Scholar
49	Lin M, Zhang Z, Gao M, Yu H, Sheng H and Huang J: MicroRNA-193a-3p suppresses the colorectal cancer cell proliferation and progression through downregulating the PLAU expression. Cancer Manag Res. 11:5353–5363. 2019.PubMed/NCBI View Article : Google Scholar
50	Ai C, Zhang J, Lian S, Ma J, Győrffy B, Qian Z, Han Y and Feng Q: FOXM1 functions collaboratively with PLAU to promote gastric cancer progression. J Cancer. 11:788–794. 2020.PubMed/NCBI View Article : Google Scholar
51	Hoca M, Becer E, Kabadayı H, Yücecan S and Vatansever HS: The effect of resveratrol and quercetin on epithelial-mesenchymal transition in pancreatic cancer stem cell. Nutr Cancer. 72:1231–1242. 2020.PubMed/NCBI View Article : Google Scholar